Radiopharm Theranostics Limited

RAD

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The company has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Buxton Resources Limited

BUX

Buxton Resources Ltd. engages in the business of mineral exploration. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2007-10-23. The company is focused on the discovery and development of metalliferous ore deposits, including nickel, copper, gold, iron, and graphite. Its projects include Graphite Bull Project (BUX 100%), West Kimberley Project (three separate Joint Ventures with IGO - BUX 16% - 20%), Fraser Range Project (BUX 10%/IGO 90%), Narryer Project (BUX 100%), Copper Wolf Project (BUX 49%/IGO earning 51% on certain tenements), Centurion Project (BUX 100%), Shogun & Royale Projects (BUX 100%), Lateron Project (BUX 100%), and Madman Project (BUX 100%). The Graphite Bull Project is located 280 km East of Carnarvon in the Murchison Region of Western Australia. The West Kimberley Project is targeting Nova-style magmatic Ni-Cu sulphide mineralization in Proterozoic belts of the West Kimberley Region of Western Australia. The Narryer Project is targeting magmatic Ni-Cu-PGE sulphide mineralization along the Yilgarn Craton margin within the Murchison Region of WA.

Core Lithium Ltd

CXO

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2011-02-11. The company owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Napperby Uranium, Yerelina and Mt Freeling, and Blueys-Inkheart. The Shoobridge Lithium Project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. The Anningie and Barrow Creek encompass eight exploration licenses over approximately 2,000 km2 in and around the Anningie and Barrow Creek tin-tantalum pegmatite fields in the Northern Territory. Napperby is an advanced uranium project within the central Northern Territory.

Arafura Rare Earths Ltd

ARU

Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Company’s primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.